Senior Advisor, Clinical Research, Oncology at Eli Lilly and Company

Shanghai, Shanghai, China

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceutical, HealthcareIndustries

Requirements

Medical Doctor. Must be board eligible or certified in appropriate specialty
≥ 2 years, or 4 years, or 8 years experience of being clinical research physician or medical advisor in pharma industry, when applying different levels of CRP role. Knowledge of drug development process is preferred
Demonstrated ability to balance scientific priorities with business priorities
Demonstrated ability to influence others (both cross-functionally and within the function) in order to create a positive working environment
Ability to engage in domestic and international travel to the degree appropriate to support the business of the team
Fluent in English, verbal and written communication

Responsibilities

Provide medical expertise to clinical strategic planning and execution, all aspects of the local business, and enhance the customers' experience in scientific interaction with Eli Lilly
Take core role in collaborating with the global teams (or leading if assigned for China lead multi-country study) in the clinical development strategy, study planning, designing, startup and conduct of phase I-IV clinical trials, analysis and reporting of China data (or study data), as well as non-clinical trial solutions/activities that are conducted in China
Take core role and collaborate with registration affairs staff in communicating with health authorities during clinical trial permission (CTP) and new drug application (NDA) process
Take a leadership role in defining the patient Journey, evidence gap, and developing integrated evidence generation plan and medical strategy. Become patient advocate, as well as a medical expert
Contribute actively on an ongoing basis to the strategic planning for currently marketed brands and support brand commercialization activities during the development of the local business plan
Contribute as a scientific and medical expert to activities and deliverables of the PRA organization, in particular giving clinical input and insight to develop payer partnership programs and defend the product value, supporting negotiation strategy development and dossier preparation
Strategically lead and contribute on planning and execution of medical meetings (scientific exchange meetings, advisory board meetings, and/or other meetings with health care professionals), real world study, data analysis and publication development (abstracts, posters, manuscripts) while ensuring compliance
Establish and maintain appropriate collaborations and relationships with external scientific experts, thought leaders, and the general medical community

Skills

Oncology

Hematology

Clinical Trials

Drug Development

Medical Affairs

Phase I-IV Trials

Study Design

Regulatory Affairs

NDA

CTP

Medical Strategy

Patient Journey

Evidence Generation

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free